Every 424B that NeOnc Technologies Holdings, Inc. (NTHI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NTHI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NTHI filings page.
NeOnc Technologies Holdings, Inc. (NTHI) is conducting a registered direct offering of 2,610,715 shares of common stock and 960,715 pre-funded warrants, together with 3,571,430 five-year warrants, at a combined price of $4.20 per share (or pre-funded warrant) and accompanying warrant, for gross proceeds of $15.0 million and estimated net proceeds of $13.9 million.
Each share or pre-funded warrant is sold with one warrant exercisable at $4.20 per share, with pre-funded warrants exercisable at $0.0001 per share, both immediately upon issuance, subject to 4.99% or 9.99% beneficial ownership limits. Common stock outstanding is expected to increase to 29,766,095 shares assuming full exercise of the pre-funded warrants and no exercise of the warrants.
NeOnc, an emerging growth and smaller reporting clinical-stage biopharmaceutical company focused on brain cancers, reports it has generated $0 in revenue from January 1, 2023 to June 30, 2026 and incurred a net loss of $23.1 million for the six months ended June 30, 2026, with an accumulated deficit of $135.8 million
NeOnc Technologies Holdings, Inc. is registering for resale up to 555,554 shares of Common Stock, consisting of 277,777 issued shares and 277,777 shares issuable upon exercise of a Warrant. The registration enables the named selling stockholder to offer and sell the Shares from time to time at fixed or prevailing market prices or by negotiated transactions. The Company is not selling shares hereunder and will not receive proceeds from resales, although the Company may receive cash proceeds if the Warrant is exercised for cash. The Warrant has a $9.00 exercise price, a five-year term and beneficial ownership exercise limits (4.99%/9.99% features). Shares outstanding were 25,933,365 as of June 12, 2026.
NeOnc Technologies Holdings, Inc. is registering 680,558 shares of Common Stock for resale by selling stockholders. The 680,558 shares consist of 340,279 currently issued shares and 340,279 shares issuable upon exercise of Warrants exercisable at $9.00 per share and expiring five years from issuance. The resale registration covers shares issued in several private placement closings and is being filed to satisfy registration rights granted to the selling holders. The Company will not receive proceeds from resales by the selling holders; it would receive proceeds only if Warrants are exercised for cash rather than on a cashless basis. Common stock outstanding was 24,911,482 shares as of April 8, 2026, and the last reported Nasdaq sale price was $5.37 per share.
NeOnc Technologies Holdings, Inc. files a prospectus supplement to offer up to $75,000,000 of Common Stock in an at-the-market program through BTIG, LLC and A.G.P./Alliance Global Partners under an Equity Distribution Agreement dated April 10, 2026. The company may sell shares from time to time at prevailing market prices; proceeds are intended to pay approximately $7.0 million of withholding tax obligations, fund clinical trials, and provide working capital. The offering cites up to 38,877,962 shares outstanding after this offering under an illustrative sale assumption and reports 24,911,482 shares outstanding currently. Sales are discretionary, there is no minimum offering amount, and Placement Agents will receive a 3.0% commission on gross proceeds.
NeOnc Technologies Holdings, Inc. is registering up to 2,950,498 shares of common stock for resale by existing investors, including 1,475,249 outstanding shares and 1,475,249 shares issuable upon warrant exercise. The company is not selling shares itself and will only receive cash if the warrants, exercisable at $9.00 for five years, are exercised for cash, which would be used for general corporate purposes.
Shares outstanding were 22,692,159 as of January 29, 2026 and would be 24,167,408 if all warrants are exercised. NeOnc is a clinical‑stage biopharmaceutical company developing intranasal and oral therapies for aggressive brain cancers, led by NEO100 and NEO212. It reported minimal revenue, large recurring net losses (including a $46.6 million loss for the nine months ended September 30, 2025) and has substantial doubt about its ability to continue as a going concern.
NeOnc Technologies Holdings (NTHI) filed a Rule 424(b)(4) prospectus supplement to its S-1, updating the base prospectus by attaching recent Quarterly and Current Reports. Its common stock trades on Nasdaq as NTHI.
For the quarter ended March 31, 2025, NeOnc reported a net loss of $38,001,987 on revenue of $39,990, driven by $23,073,745 in share-based compensation and an $11,328,565 advisory fee tied to its Nasdaq listing. Cash and cash equivalents were $5,439,210 at quarter-end. The company completed a private placement totaling $11,644,005, released to the company after its registration statement became effective.
Management disclosed substantial doubt about continuing as a going concern. Liquidity tools include a $10.0 million related-party line of credit (with warrants) and a $50.0 million equity purchase agreement; no borrowings or puts were utilized as of March 31, 2025. Shares outstanding were 19,026,776 as of May 9, 2025. The filing references material weaknesses in internal control over financial reporting.